Early glaucoma progression leaves a mark, and not just on visual fields. For Dr. I. Paul Singh, the goal is simple: intervene before damage settles in.
In this interview, Dr. Singh shares why early, physiologic, tissue-preserving canaloplasty fits naturally into glaucoma care today. With iTrack™ Advance, surgeons can reduce drop burden, address compliance challenges sooner and still preserve future treatmentMIGS options.
He also highlights what makes the Nova Eye collaboration meaningful: shared values, real science and a commitment to doing right by patients.
Learn more at https://itrack-advance.com/.
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
